Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 368.36 USD 0.41% Market Closed
Market Cap: 48.7B USD

Wall Street
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 496.56 USD with a low forecast of 238.36 USD and a high forecast of 609 USD.

Lowest
Price Target
238.36 USD
35% Downside
Average
Price Target
496.56 USD
35% Upside
Highest
Price Target
609 USD
65% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
HPHA
Heidelberg Pharma AG
77% Upside
ARGX
argenx SE
24% Upside
ARX
Aroa Biosurgery Ltd
14% Upside
QTTB
Homology Medicines Inc
221% Upside
ARQT
Arcutis Biotherapeutics Inc
22% Upside
688428
InnoCare Pharma Ltd
80% Upside
688331
RemeGen Co Ltd
10% Downside
EXEL
Exelixis Inc
2% Upside

Revenue
Forecast

Revenue Estimate
Alnylam Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 29%. The projected CAGR for the next 4 years is 38%.

29%
Past Growth
38%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALNY's stock price target?
Price Target
496.56 USD

According to Wall Street analysts, the average 1-year price target for ALNY is 496.56 USD with a low forecast of 238.36 USD and a high forecast of 609 USD.

What is Alnylam Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
38%

For the last 13 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 29%. The projected CAGR for the next 4 years is 38%.

Back to Top